Knudsen, Cecilie
Belfakir, Selma B.
Degnegaard, Pelle
Jürgensen, Jonas A.
Haack, Aleksander M.
Friis, Rasmus U. W.
Dam, Søren H.
Laustsen, Andreas H.
Ross, Georgina M. S.
Funding for this research was provided by:
Innovationsfonden (9066-00007B, 2052-00023B)
Article History
Received: 25 October 2023
Accepted: 11 January 2024
First Online: 31 January 2024
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Cecilie Knudsen is a co-founder of, shareholder in, investor in and employed by VenomAid Diagnostics ApS. Selma Belfakir is employed by VenomAid Diagnostics ApS. Pelle Degnegaard is employed by VenomAid Diagnostics ApS. Jonas A. Jürgensen is a co-founder of, shareholder in and employed by VenomAid Diagnostics ApS. Søren H. Dam is a co-founder of, shareholder in and investor in VenomAid Diagnostics ApS. Aleksander M. Haack is a co-founder of and shareholder in VenomAid Diagnostics ApS. Rasmus U. W. Friss is a co-founder of, shareholder in and investor of VenomAid Diagnostics ApS. Prof. Andreas H. Laustsen is a co-founder of, shareholder in and investor in VenomAid Diagnostics ApS. Dr. Georgina M. S. Ross is employed by VenomAid Diagnostics ApS. Authors declare no other competing interests.